Skip to main content
. 2021 Mar 12;11:620214. doi: 10.3389/fonc.2021.620214

Figure 4.

Figure 4

Potential mode of action of cell cycle inhibitors in hormone-responsive breast tumors. There are numerous anti-cancer strategies that specifically target cell proliferation in breast cancer. The dependence of the HR+ve cells on Rb/E2F/CDK4/6 axis for progression through restriction point makes them vulnerable for CDK4/6 inhibitors.